Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
One Percent Rule Checklist For Safer Forex Trading Risk 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
CANTON, Mass., April 20, 2017 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 42nd Annual Deutsche Bank Healthcare Conference in Boston. The presentation will take place at 10:40 a.m. ET on Wednesday, May 3, 2017 at the InterContinental Boston Hotel.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact: Alex Dasalla [email protected]
